Myung In Pharmaceutical LTD. (KRX:317450)
South Korea flag South Korea · Delayed Price · Currency is KRW
45,400
-1,750 (-3.71%)
At close: Aug 21, 2026

KRX:317450 Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
88,85481,43568,67174,51257,43459,750
Depreciation & Amortization
10,16010,94012,46311,44011,33611,619
Loss (Gain) From Sale of Assets
-20.99-20.99609.540.32-10.7-6.39
Loss (Gain) From Sale of Investments
--8,310-826.42--
Provision & Write-off of Bad Debts
221.51525.33-306.2560.61-207.87165.58
Other Operating Activities
2,7111,016-1,5223,787924.412,025
Change in Accounts Receivable
724.75101.37941.39262.812,166579.21
Change in Inventory
-17,704-4,537-5,205-8,679-1,264-2,511
Change in Accounts Payable
1,985-1,9775,789268.26-115.86236.65
Change in Other Net Operating Assets
-9,050-5,922-6,777-4,750-9,217-5,754
Operating Cash Flow
77,88281,56182,97276,07561,04566,105
Operating Cash Flow Growth
-16.04%-1.70%9.07%24.62%-7.65%20.04%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-46,088-30,039-10,189-4,647-3,402-2,697
Sale of Property, Plant & Equipment
23.0623.06180.61-13.56
Sale (Purchase) of Intangibles
-2,099-4,808-3.26-1.43-0.56319.08
Investment in Securities
-221,096-228,705-66,883-28,866-68,030-65,086
Other Investing Activities
-0---6,295-17,527-5,915
Investing Cash Flow
-269,260-263,529-76,895-39,810-88,946-73,374

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Issued
---3,8405,4801,052
Total Debt Issued
---3,8405,4801,052
Long-Term Debt Repaid
--1,469-2,075-1,459-1,492-1,422
Total Debt Repaid
-1,482-1,469-2,075-1,459-1,492-1,422
Net Debt Issued (Repaid)
-1,482-1,469-2,0752,3813,989-369.77
Issuance of Common Stock
193,782193,782----
Dividends Paid
-21,900-11,200-5,600-22,400-11,200-14,000
Other Financing Activities
-0-0----
Financing Cash Flow
170,400181,113-7,675-20,019-7,211-14,370

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-49.6-250.0145.27-48.1396.584,102
Miscellaneous Cash Flow Adjustments
0-----
Net Cash Flow
-21,028-1,105-1,55216,198-34,716-17,537

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
31,79451,52272,78371,42857,64363,407
Free Cash Flow Growth
-57.65%-29.21%1.90%23.91%-9.09%39.39%
Free Cash Flow Margin
10.85%17.94%27.01%29.47%25.52%30.30%
Free Cash Flow Per Share
2300.234250.246498.196377.485146.685661.37
Levered Free Cash Flow
4,54327,58960,20551,01848,30956,598
Unlevered Free Cash Flow
4,68327,73660,40651,22748,37656,681

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
-----137.2
Cash Income Tax Paid
21,93822,45422,78216,30026,81215,695
Change in Working Capital
-24,044-12,335-5,252-12,898-8,430-7,449